Invicro
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Invicro sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).
Invicro: 14 sponsored US clinical trials, 2 recruiting.
Invicro sponsors 14 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 12 completed. 0 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Parkinson's Disease (Disorder), with 1 trials.
Top-decile sponsor footprint
Invicro ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
12 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
14 total, page 1 of 1
Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
NCT07348250
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
NCT07348276
Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein
NCT05274568
Plasma P-tau2017 and Quantitative Amyloid PET Imaging
NCT05164536
Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444
NCT05009199
Evaluation of [18F]APN-1607 as a PET Biomarker
NCT05005819
Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain
NCT06445465
Assessment of the Biodistribution and Safety of [18F]MNI-1054
NCT03719482
D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562
NCT03686501
Assessment of [18F]MNI-1054 as a Marker for LSD1
NCT03695926
Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss
NCT03587649
Phase 1 Test-retest Evaluation of [18F]MNI-958 PET
NCT03545789
Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects
NCT03472313
Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein
NCT03071224
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
What is open in the Invicro pipeline
2 recruiting of 14 indexed (14% open); 12 completed (86%).
Phase mix: 0 late (III/IV) vs 14 early (I/II) (early-phase heavy).
Top condition: Parkinson's Disease (Disorder) (1 trial), 7 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Invicro: open-pipeline peers nationwide
Peers matched on 14 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Invicro sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 14 trials (± recruiting share)
- 3-C Institute for Social Development · 14 trials · 0% recruiting
- Abbott Medical Optics · 14 trials · 0% recruiting
- Abbott RDx Cardiometabolic · 14 trials · 0% recruiting
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · 14 trials · 0% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this Invicro page
14 registered trials is a research-attention snapshot, not an endorsement of Invicro or any single study.
- 2 of Invicro's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Parkinson's Disease (Disorder) is the condition Invicro studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Parkinson's Disease (Disorder) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Invicro pipeline card: 14 registered trials from official public datasets.Report a data error.